Figure 5.

Human CD8⁺ T cells are depleted after administration of CD8-depleting antibody. (a) Experimental outline. NSG/BLT mice were administered CD8-depleting antibody (CD8-depleted, n = 8, 3 mg/kg i.v.) or vehicle (CD8-intact, n = 7) 4 days prior to administration of CD19xCD3 DART protein to all mice (1 mg/kg i.v.). Peripheral blood (PB) was collected and analyzed at 4 days and 1 day prior to and at days 3, 7, and 14 after administration of CD19xCD3 DART protein; tissues were harvested and analyzed at day 15. (b) Percent CD8⁺ cells out of CD3⁺ cells and (c) number CD8⁺ cells per microliter detected in PB by flow cytometry (CD8-depleted in orange, CD8-intact in green). (d) Percent CD8⁺ cells out of CD3⁺ cells and (e) number CD8⁺ cells detected in tissues by flow cytometry. (Mean ± SEM plotted. P values were calculated in b and c by repeated-measures two-way analysis of variance with Sidak’s multiple comparisons test, comparing CD8-depleted versus CD8-intact. P values were calculated in d and e by unpaired t-test, comparing CD8-depleted versus CD8-intact. ns, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.)